Methicillin-resistant | German Center for Infection Research

Short description

A bacterium that is methicillin-resistant can neutralize the effect of this antibiotic.

Detailed description

Methicillin is a beta-lactam antibiotic, which is used to treat infections with bacteria. In case of methicillin resistance, this is no longer possible. Particularly methicillin-resistant Staphylococcus aureus () have become a clinical problem as they cannot be treated with standard antibiotics any more.

Several mustard-coloured, spherical bacteria in the middle of much smaller blue-coloured blood cells.

Phage lysin compound HY-133: Start of clinical phase I “first-in-human” study to eliminate Staphylococcus aureus in the nasal microbiome

The novel active agent HY-133, which was developed by HYpharm and prepared for clinical trials in collaboration with the German Center for Infection Research (DZIF) and universities in Tübingen

Innovative Phage Lysin HY-133 enters phase I clinical study

HYpharm's innovative preventive agent HY-133 has reached the first clinical trial phase. HY-133 is specifically effective against the bacterial pathogen Staphylococcus aureus including multi-resistant

The photo shows a group of four researchers (three women and one man) in white lab coats in a laboratory.

Researchers decode new antibiotic agent

More and more bacterial pathogens are developing resistance. There is an increasing risk that current drugs will no longer be effective against infectious diseases. Scientists around the world are

Several silver-coloured bioreactors with many connecting tubes and control screens used for fermentation and production of active agents.

Clinical development of two antimicrobial agents funded by Else Kröner-Fresenius Foundation

The Else Kröner-Fresenius Foundation's ForTra gGmbH for Research Transfer—the largest medicine-funding foundation in Germany—supports the legally compliant production of new drug candidates for direct

Dec 2022

Pharmaceutics

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant Staphylococcus aureus

Autoren

Rox K et al.

Electron micrograph of a cluster of rod-shaped bacterial cells in gray.

New drug candidate found against persistent intestinal pathogens

Infections with the bacterium Clostridioides difficile (C. difficile for short) frequently recur due to permanent stages remaining in the intestine. A drug that also effectively combats the permanent

Saarbrücken antibiotics project funded by INCATE incubator

With INCATE (INCubator for Antibacterial Therapies in Europe), the German Center for Infection Research (DZIF) has participated in the foundation of a European initiative to take up the fight against

Sep 2014

PLoS One

Phenotypic and genotypic characterization of daptomycin-resistant methicillin-resistant Staphylococcus aureus strains: relative roles of mprF and dlt operons

Autoren

Mishra NN et al.

Bonn - Köln

Antibacterial Vaccines and Diagnostics Development (ACTIVATE)

The DZIF working group "Antibacterial Vaccines and Diagnostics Development" (ACTIVATE) led by Alexander Klimka develops active and passive vaccines against bacterial pathogens and antibody-based rapid tests to detect antibiotic-resistant bacteria. In 2017, the World Health Organization (WHO) ...

New group of antibacterial molecules identified

Researchers at Karolinska Institutet, Umeå University, and DZIF scientists at the University of Bonn have identified a new group of molecules that have an antibacterial effect against many antibiotic